meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic, hormone-sensitive prostate cancer
11
renal cell cancer (RCC)
endocrine therapy
androgen deprivation therapy (ADT)
abiraterone plus ADT
abiraterone plus docetaxel plus ADT
apalutamide plus ADT
darolutamide plus doxetaxel plus ADT
docetaxel plus ADT
enzalutamide
enzalutamide plus ADT
versus all
vs endocrine therapy
vs androgen deprivation therapy (ADT)
vs docetaxel plus ADT
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
deaths (OS)
metastatic, hormone-sensitive prostate cancer
metastatic, hormone-sensitive prostate cancer
versus androgen deprivation therapy (ADT)
apalutamide plus ADT vs. androgen deprivation therapy (ADT)
1
certainty unassessable
statistically conclusive
-30%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open